Group a streptococcal emm type prevalence among symptomatic children in cape town and potential vaccine coverage

Pediatric Infectious Disease Journal

Volumn 33, Issue 2, 2014, Pages 208-210

  Engel, Mark E ^a   Muhamed, Babu ^a   Whitelaw, Andrew C ^b   Musvosvi, Munyaradzi ^b   Mayosi, Bongani M ^a   Dale, James B ^c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

rheumatic heart disease; streptococcal pharyngitis, emm types; vaccine coverage

Indexed keywords

STREPTOCOCCUS VACCINE;

ADOLESCENT; ARTICLE; BACTERIUM ISOLATION; CHILD; CONTROLLED STUDY; DEMOGRAPHY; DNA EXTRACTION; FEMALE; GROUP A STREPTOCOCCAL INFECTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; PHARYNGITIS; PREDICTION; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; RHEUMATIC FEVER; SCHOOL CHILD; SEQUENCE DATABASE; STREPTOCOCCAL PHARYNGITIS;

ADOLESCENT; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CARRIER PROTEINS; CHILD; CHILD, PRESCHOOL; HUMANS; MOLECULAR EPIDEMIOLOGY; PHARYNGITIS; PREVALENCE; RHEUMATIC FEVER; SOUTH AFRICA; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES;

EID: 84893025754     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182a5c32a     Document Type: Article

References (14)

1. Bisno AL. Group A streptococcal infections and acute rheumatic fever. N Engl J Med. 1991;325783-793
2. Carapetis JR, Steer AC, Mulholland EK, et al. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5685-694
3. Jackson SJ, Steer AC, Campbell H. Systematic Review Estimation of global burden of non-suppurative sequelae of upper respiratory tract infection rheumatic fever and post-streptococcal glomerulonephritis. Trop Med Int Health. 2011;162-11
4. Wilson N. Rheumatic heart disease in indigenous populations-New Zealand experience. Heart Lung Circ. 2010;19282-288
5. Parnaby MG, Carapetis Jr. Rheumatic fever in indigenous Australian children. J Paediatr Child Health. 2010;46527-533
6. Sliwa K, Carrington M, Mayosi BM, et al. Incidence and characteristics of newly diagnosed rheumatic heart disease in urban African adults insights from the heart of Soweto study. Eur Heart J. 2010;31719-727
7. Steer AC, Carapetis Jr. Prevention and treatment of rheumatic heart disease in the developing world. Nature reviews. 2009;6689-698
8. Remenyi B, Carapetis J, Wyber R, et al. Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease. Nat Rev Cardiol. 2013;10284-292
9. Dale JB, Penfound TA, Chiang EY, et al. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine. 2011;298175-8178
10. Engel M. A Study of Determinants and Prevalence of Rheumatic Heart Disease in Cape Town. Cape Town, South Africa University of Cape Town; 2013
11. CDC Streptococcal Reference Page. Available at ftpftp.cdc.govpub infectious diseasesbiotechtstransl. Accessed April 18, 2013
12. Dale JB, Penfound TA, Tamboura B, et al. Potential coverage of a multivalent M protein-based group A streptococcal vaccine. Vaccine. 2013;311576-1581
13. Steer AC, Law I, Matatolu L, et al. Global emm type distribution of group A streptococci systematic review and implications for vaccine development. Lancet Infect Dis. 2009;9611-616
14. Lancefield RC. Current knowledge of type-specific M antigens of group A streptococci. J Immunol. 1962;89307-313